Harinder Gill

机构：Queen Mary Hospital, University of Hong Kong

发表论文 188 篇 · 总被引 3450 次 · h-index 31

代表论文

• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study (2024 · Blood · 被引 9)
• Cross-cultural adaptation and validation of the Chinese version of the quality of communication questionnaire (2025 · BMC Palliative Care · 被引 3)
• A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma (2024 · Blood · 被引 3)
• Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer? (2024 · Expert Review of Hematology · 被引 3)
• VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV). (2024 · Journal of Clinical Oncology · 被引 3)